Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) EBIT Margin (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed EBIT Margin for 4 consecutive years, with 21.85% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 661355.0% to 21.85% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 154.73% through Dec 2025, up 228276.0% year-over-year, with the annual reading at 154.73% for FY2025, 228276.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 21.85% at Orchestra BioMed Holdings, up from 2359.23% in the prior quarter.
  • The five-year high for EBIT Margin was 21.85% in Q4 2025, with the low at 6591.7% in Q4 2024.
  • Average EBIT Margin over 4 years is 2153.76%, with a median of 2035.35% recorded in 2022.
  • The sharpest move saw EBIT Margin crashed -387272bps in 2023, then surged 661355bps in 2025.
  • Over 4 years, EBIT Margin stood at 891.02% in 2022, then plummeted by -435bps to 4763.74% in 2023, then tumbled by -38bps to 6591.7% in 2024, then soared by 100bps to 21.85% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 21.85%, 2359.23%, and 2311.84% for Q4 2025, Q3 2025, and Q2 2025 respectively.